患者参与者对长效卡替拉韦和利匹韦林实施的看法：来自欧洲地点卡替拉韦和利匹韦林实施研究（CARISEL）的研究结果。
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
机构信息
ViiV Healthcare, Durham, NC, USA.
Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
出版信息
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837.
INTRODUCTION
CARISEL is an implementation-effectiveness "hybrid" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.
METHODS
PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.
RESULTS
Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations.
CONCLUSIONS
PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.
简介
CARISEL 是一项实施效果的“混合”研究，研究了 5 个欧洲国家中，感染 HIV-1 的人群（患者研究参与者 [PSP]）对每 2 个月（Q2M）注射一次卡替拉韦（CAB）加利匹韦林（RPV）长效（LA）制剂的看法。
方法
PSP 在首次（第 1 个月 [M]1）、第三次（M4）和第七次（M12）注射就诊时，完成了关于可接受性（干预措施可接受性测量）、适宜性（干预措施适宜性测量）和可行性（干预措施可行性测量）的问卷。还进行了半结构化定性访谈。
结果
共有 437 名 PSP 参与了该研究，其中 430 名接受了治疗。中位（四分位间距）年龄为 44（37-51）岁，25.3%（n=109/430）为女性（出生性别），21.9%（n=94/430）为有色人种。在各个时间点，PSP 均认为 CAB+RPV LA 高度可接受、适宜且可行（平均评分≥4.47/5）。定性数据支持了这些观察结果。
结论
PSP 认为 CAB+RPV LA Q2M 是一种可接受、适宜且可行的治疗选择。
Zotero 插件